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Chemokines are chemoattractant cytokines, characterised by the
presence of a conserved cysteine motif adjacent to the N-terminus.
They are subdivided into 2 major groups: the CC chemokines and
the CXC chemokines, in which the first 2 cysteine residues are
either adjacent or separated by one amino acid, respectively (Clore
and Gronenborn, 1995). Individual chemokines selectively attract
leukocyte subsets through chemoattraction and by activating
leukocyte integrins to bind their adhesion receptors on endothelial
cells (Ebnet and Vestweber, 1999). The CXC chemokines act
predominantly on neutrophils and T-lymphocytes, while the CC
chemokines are active on various cell types, including monocytes
and lymphocytes. Chemokines exert their effects by binding to 7
transmembrane domain G protein-coupled receptors. 11 receptors
for the CC chemokines (CCR1-11) and 5 receptors for the CXC
chemokines have been identified (Wang et al, 1998; Schweickart
et al, 2000; Zlotnik and Yoshie, 2000). Their ligands bind to 
the extracellular N-terminus, leading to phosphorylation of
serine/threonine residues on the cytoplasmic C-terminus,
signalling and receptor desensitisation (Turner et al, 1998). There
is apparent redundancy in the system; each receptor can respond to
more than one chemokine; most chemokines can use more than
one receptor, and each leukocyte subset may express several
receptors. Yet the importance of individual chemokines is shown
in transgenic and knockout mice (Gao et al, 1997; Kurihara et al,
1997; Lu et al, 1998). Specific chemokines are associated with
distinct inflammatory infiltrates in a number of diseases, and
chemokine antagonists have activity in experimental models
(Takeya et al, 1993; Car et al, 1994; Baggiolini and Moser, 1997;
Howard et al, 1999). However, in most tissues there is likely to be
a complex chemokine/receptor network. 
We have been studying the chemokine network in human
epithelial ovarian cancer. This tumour microenvironment is a vari-
able mixture of epithelial tumour cells, stromal fibroblasts,
endothelial cells and infiltrating leukocytes, which are mainly
CD68+ macrophages and CD8+ lymphocytes (Negus et al, 1997).
The cytokine context of these tumours generally comprises
inflammatory cytokines, growth factors and chemokines, but there
is a lack of lymphocyte-associated cytokines (Burke et al, 1996). 
The presence of macrophages and lymphocytes in this tumour
microenvironment is related to local production of chemokines
(Bottazzi et al, 1985; Yoong et al, 1999). We reported a relation-
ship between lymphocyte and macrophage counts in ovarian
tumours and mRNA expression of the CC chemokine CCL2
(MCP-1) by tumour cells and macrophages (Negus et al, 1997).
The cytokine TNF-α , also present in the epithelial tumour islands
may regulate this CCL2 production (Negus et al, 1995). We also
found that mRNA for other CC chemokines, CCL3 (MIP-1α ),
CCL4 (MIP-1β ) and CCL5 (RANTES), localised to leukocytes in
the tumour (Negus et al, 1997), suggesting that a chemokine
network existed. However, it was not clear how this network was
controlled. Changes in the profile of chemokine receptors
expressed by individual cells can inhibit cell migration or change
their path. Thus, to understand the chemokine network in a tissue,
both chemokine and chemokine receptor expression must be
studied. 
In this paper we have compared CC chemokine receptor mRNA
expression in solid tumours with the expression of CC chemokine
mRNA. In spite of abundant CC chemokine expression in ovarian
tumours, we have found that CC chemokine receptor expression is
weak or absent in the solid tumour microenvironment. CCR1
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was the only chemokine receptor consistently expressed in the
solid tumours. This receptor localised to infiltrating CD68+
macrophages and CD8+ lymphocytes. There was no evidence that
the CC chemokine receptors studied were expressed by epithelial
tumour cells. The microenvironment of solid tumours may down-
regulate expression of some chemokine receptors and we present
preliminary evidence that hypoxia, which is a common feature of
solid tumours (Vaupel et al, 1998), may up-regulate CCR1. 
MATERIALS AND METHODS 
Samples 
25 biopsies from human ovarian tumours were obtained at opera-
tion and snap frozen into liquid nitrogen. These were classified as
serous adenocarcinoma (19), clear cell carcinoma (2), mucinous
adenocarcinoma (1), anaplastic carcinoma (1), signet ring carci-
noma (1) and endometrioid carcinoma (1). Sections for in situ
hybridisation were mounted on baked glass slides coated with 3-
aminopropyl-triethoxy-silane, air dried, and stored at –70˚C. Serial
sections were cut onto poly-L-lysine-coated slides and stored at 
–70˚C. Control peripheral blood mononuclear cells (PBMC) were
isolated from heparinised venous blood or cytophoresis buffy coats
from normal volunteers by Ficoll-Hypaque density centrifugation
(Lymphoprep™, Nycomed, Birmingham, UK). 
RNA extraction and RT-PCR 
Total RNA was prepared from all samples using Tri Reagent™
(Sigma, Poole, UK). Solid tumour biopsies were homogenised
in Tri Reagent™ using an Ultra-turrax T25 tissue homogeniser
(Janke & Kunkel, Staufen, Germany). For RT-PCR and RNase
protection analysis, total RNA was DNase-treated to remove cont-
aminating genomic DNA, using RNase-free DNase I (Pharmacia
Biotech, St Albans, UK). cDNA was synthesised from DNase-
treated total RNA using the Ready-to-Go™ T-primed First Strand
kit (Pharmacia Biotech, UK). The primers for CCL2, CCL22
(MDC) and CCR1 were designed from sequences submitted to
Genbank, using Primer 3.0. CCL3 and CCL4, CCL5 and CCL8
primer sequences were from (Hosaka et al, 1994), (Mattei et al,
1994) and (Van Coillie et al, 1997) respectively. The primer
sequences and product sizes for CCL2, CCL22 and CCR1 are: 
CCL2 For   CAAACTGAAGCTCGCACTCTCGCC
Rev   ATTCTTGGGTTGTGGAGTGAGTGTTCA
Product = 354 bp 
CCL22 For CCCTACCTCCCTGCCATTAT 
Rev CAGGGAGCTAGAACCCAACA
Product = 338 bp 
CCR1 For AAAGCCTACGAGAGTGGAAGC 
Rev AGAGGAAGGGGAGCCATTTA
Product = 426 bp 
25 µ l volume per sample was used, containing 200 ng cDNA, 1 U
AmpliTaq DNA polymerase, GeneAmp PCR buffer, GeneAmp
dNTPs (all from Perkin Elmer, Beaconsfield, UK) and 4µ M each
primer. The following protocol was used in a GeneAmp® PCR
System 9700 thermal cycler: 94˚C (5 min); 35 cycles 94˚C (30 s),
60˚C (30 s), 72˚C (30 s); 72˚C (7 min). PCR products were elec-
trophoresed through 1.2% agarose gel and visualised by ethidium
bromide. 123 bp markers (Gibco BRL, Paisley, UK) were used to
estimate band sizes. PCR products were gel extracted and
sequenced to confirm their identity. 
RNase protection assay (RPA) 
The hCR5 template set from Pharmingen (Becton Dickinson,
Oxford, UK) contained DNA templates for CCR1, CCR2, CCR2a,
CCR2b, CCR3, CCR4, CCR5, CCR8, GAPDH and L32. RPA
was carried out using [α 35S]UTP (Amersham International plc,
Aylesbury, UK) instead of [α 32P]UTP. The RNase-protected frag-
ments were run out on an acrylamide-urea sequencing gel (BioRad
Laboratories Ltd, Hemel Hempstead, UK), which was then
adsorbed to filter paper and dried under vacuum. Autoradiography
was subsequently carried out using Kodak Biomax MS film with a
Transcreen LE-intensifying screen (Sigma). 
In situ hybridisation (ISH) 
[α 35S]UTP-labelled antisense and sense riboprobes were gener-
ated from 1100 bp fragments of CCR1 and CCR4 cDNA cloned in
pcDNA1 (Stratagene, Cambridge, UK), using Sp6 and T7 RNA
polymerases (Promega Ltd, Southampton, UK). These cDNAs
were a kind gift from Antonio Sica (Mario Negri Institute, Milan,
Italy). Antisense β -actin was used as a positive control in all
experiments. In situ hybridisation was carried out using the
method described in (Naylor et al, 1990). Image capture was with
Image Grabber PCI (Neotech Ltd, London, UK). 
Immunohistochemistry 
Cryostat sections were fixed in 4% paraformaldehyde in PBS for 5
minutes. Sections were preincubated with normal rabbit serum
(DAKO, Ely, UK) at a 1/25 dilution, for 15 minutes before appli-
cation of the primary antibody. Sections were then incubated for
30 minutes at room temperature with the anti-CD8 mAb DK25
(DAKO) diluted 1/100; then biotinylated rabbit anti-mouse IgG
and avidin-biotin-peroxidase complex (both DAKO). The final
incubation was with the chromogen 3,3′ -diaminobenzidine
tetrahyrdochloride. Toluidine blue was used as the counterstain. 
Hypoxic culture 
2 × 106 THP-1 cells (purchased from the American Type Culture
Collection, Rockville, MD) were cultured in 2 ml serum-free
RPMI 1640 supplemented with 0.1 % BSA and 50 µ M β -mercap-
toethanol, in each well of a 6-well plate. The cells were then incu-
bated for up to 24 h at 37˚C under normoxia (5% CO2, in air) or
hypoxia (gassed with 5% CO2, balanced N2 until < 0.1% O2,
unpublished data) in a modular incubation chamber. 
Northern analysis 
Total RNA (15 µ g) was run on a 1% agarose-formaldehyde gel as
described in (Turner et al, 1999). Densitometric analysis was
carried out using NIH Image 1.61. 
Cell counting and statistics 
The CCR1 expressing cells in 15 High Power Fields (HPF) were
compared with the number of CD8+ cells in 15 HPF in the serial
section. 15 HPF corresponded to a total tumour area of 1.095 mm2,
892 C Scotton et al 
British Journal of Cancer (2001) 85(6), 891–897 © 2001 Cancer Research Campaign
BJOC 01-2020 891-897  10/9/01  2:14 pm  Page 892so the counts were expressed as cells mm–2. As the data were not
normally distributed, the nonparametric Spearman’s rank correla-
tion was used to calculate P values (Altman, 1991). 
RESULTS 
Chemokine receptor mRNA expression in ovarian
epithelial tumours 
25 biopsies from human epithelial ovarian cancer were analysed
for chemokine receptor mRNA expression by RPA. RPA was
performed with a template set containing probes for CCR1, 2, 2a,
2b, 3, 4, 5, 8, and the ‘housekeeping’ genes GAPDH and L32. All
the CC chemokine receptor mRNAs were expressed by a control
PBMC preparation (Figure 1A). In contrast, CC chemokine
receptor mRNA was weakly expressed in the solid tumour biop-
sies. CCR1 was the only CC chemokine receptor present in the
majority of the samples, with 75% of the biopsies positive for this
receptor mRNA. Less than 15% of the biopsies were positive for
the remaining CC chemokine receptor mRNAs (Figure 1A and B). 
Leukocytes are likely to be the main source of chemokine
receptor mRNA in the tumours and their mRNA would have been
diluted by other cells in the tumour microenvironment. To
confirm the RPA results, therefore, the more sensitive technique
of RT-PCR was used on RNA from the same biopsies. No
mRNA was detected for CCR2, 2a, 2b, 3 or 5 in samples that
were negative by RPA. CCR1 was detected in those samples
positive by RPA (Figure 1C). 72% of the samples also gave a
positive signal for CCR4 although these were negative by RPA
(Figure 1C).
Characterisation of chemokine receptor mRNA
expressing cells in ovarian tumour biopsies 
We used in situ hybridisation to mRNA on frozen sections from 11
biopsies to localise CCR1 and CCR4 expression. 9 of the 11 biop-
sies were positive for CCR1 by RPA and CCR1 could be detected
on cells in these biopsies by ISH. Numbers of CCR1 expressing
cells ranged from 13.7-83.1 cells mm–2, with a median 41.4 cells
mm–2. 2 of the biopsies used for ISH were negative by RPA, yet
very occasional cells (mean 2.7 cells mm–2) could be found that
were positive for CCR1 mRNA, demonstrating the increased
sensitivity of ISH compared with RPA. CCR1 mRNA localised
mainly to clusters of cells in the stromal areas of the ovarian
tumour biopsies and the distribution was consistent with expres-
sion by infiltrating cells (Figure 2). Epithelial tumour cells did not
appear to express CCR1 mRNA. As described above, CCR4
mRNA was detected by RT-PCR but not by RPA in RNA from
solid tumours. As might be expected, individual cells expressing
CCR4 were rare (Figure 2). They were seen in 4/11 biopsies, with
only 2-3 positive cells detected in the entire section. This demon-
strates the extreme sensitivity of RT-PCR, but suggests that RPA
and ISH give more meaningful data on chemokine receptor mRNA
expression in tissue samples. Thus a combination of techniques for
measuring RNA suggests that expression of CCR 2, 3, 5 and 8 in
the solid tumour microenvironment is extremely low both in terms
of RNA and number of expressing cells, although cells that might
be expected to express these receptors are present. 
Correlation of CCR1 expression in solid tumours with
CD8 lymphocytes 
In a previous publication, we characterised the infiltrating leuko-
cytes in ovarian cancer as CD3+/CD8+/CD45RO+ lymphocytes
and CD68+ macrophages (Negus et al, 1997). In this study,
we found that many of these lymphocytes express CCR1.
Immunohistochemistry for CD8 and ISH to CCR1 mRNA was
performed on sequential sections. CCR1 expression was often
seen at the same location as CD8+ T cells in the sequential section
(Figure 3). The number of cells expressing CCR1 was counted in
15 HPF, corresponding to a total tumour area of 1.095 mm2.
Similarly, the number of cells expressing CD8 was counted in
15 HPF in the sequential section; only those cells with obvious
nuclei and good cytoplasmic staining were scored. A possible
correlation was found between the number of cells expressing
CCR1 and the number of infiltrating CD8+ T-cells in individual
Chemokine receptor expression in ovarian cancer 893
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Figure 1 (A) RNase protection assay of CC chemokine receptor
expression in normal PBMC and solid human ovarian tumour biopsies.
(B) Percentage of samples expressing CC chemokine receptor mRNA in
solid human ovarian tumours, using the data derived from the RPA shown in
Figure 1 A. Only CCR1 is expressed by the majority of solid tumours. (C)
The presence of CCR1 and CCR4 mRNA in the solid tumours was confirmed
by RT-PCR. Amplification of GAPDH is shown as a loading control 
BJOC 01-2020 891-897  10/9/01  2:14 pm  Page 893tumour sections (rs = 0.682; P = 0.031). A proportion of the cells
expressing CCR1 also had the morphological characteristics of
macrophages. Immunohistochemistry to CD68 was not of suffi-
cient quality to obtain statistical correlation with the ISH results
but there were examples of concordance between CD68 posi-
tivity and CCR1 expression on the sequential sections (data not
shown). 
A range of CC chemokine mRNA is detected in ovarian
tumours 
We used RT-PCR to screen for 6 of the CC chemokines (CCL2,
CCL3, CCL4, CCL5, CCL8 and CCL22) that bind to the receptors
studied above, in the same biopsy samples. CCL2, CCL3, CCL4,
CCL5 and CCL8, were detected in more than 80% of the solid
tumour samples, while CCL22 was detected in 6/25 samples
(Figure 4). This agrees with previous work from our laboratory
where CCL2, 3, 4 and 5 were detected by ISH (Negus et al, 1997).
Thus, a range of chemokine mRNA are expressed, despite the
variability in mRNA expression of chemokine receptors,
suggesting that their action may be controlled at the level of the
receptor. 
Regulation of CCR1 expression in the tumour
microenvironment 
A number of agents regulate CCR1 such as LPS (Sica et al, 1997),
and the cytokines IL-12, IFN-γ and IFN-α (Bonecchi et al, 1999;
Colantonio et al, 1999; Zella et al, 1999). However, these cytokines
have not been reported in ovarian tumours (Burke et al, 1996). TNF-
α is a predominant cytokine in the ovarian tumour microenviron-
ment (Naylor et al, 1993) and previous reports suggested that the
presence of this pro-inflammatory cytokine might down-regulate
the CCL2 receptor, CCR2b (Sica et al, 2000). To study the in vitro
effect of this cytokine on CCR1, we used the monocytic cell line
THP-1 which expresses both CCR1 and CCR2b mRNA. Treatment
of THP-1 cells with 1 and 10 ng ml–1 TNF-α did not influence
CCR1 mRNA expression (data not shown); 100 ng ml–1 was toxic to
the cells. Another environmental factor likely to influence cell
behaviour is intratumoural oxygen tension. We therefore studied the
influence of hypoxia on CCR1 and CCR2b expression. 
The regulation of CC chemokine receptors by hypoxia 
Regions of hypoxia are common in solid tumours due to the
chaotic and intermittent blood supply, and the high metabolic rate
894 C Scotton et al 
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Figure 2 Localisation of CCR1 and CCR4 mRNA by in situ hybridisation.
The figure shows a cluster of cells expressing CCR1, × 400 (A); a cluster of
cells expressing CCR1, × 1000 (inset); a single cell expressing CCR4, × 400
(B) and the same cell × 1000 (inset) 
CCR1
CD8+
Figure 3 Co-localisation of CCR1 expression and CD8 expression in the
same field of view in serial sections (× 400). Arrows indicate cells expressing
CCR1 
BJOC 01-2020 891-897  10/9/01  2:14 pm  Page 894of tumour cells (Vaupel et al, 1998). Macrophages accumulate in
regions of necrosis, which are usually hypoxic (Negus et al, 1998)
and hypoxia can affect the migration of THP-1 cells and mono-
cytes, but not lymphocytes (Turner et al, 1999). Thus THP-1 cells
were cultured under hypoxic conditions for 24 h, and CCR1/2b
mRNA expression was assayed by Northern blot analysis during
this time (Figure 5). After 24 h hypoxia, the expression of CCR1
mRNA (normalised for the housekeeping gene, β -actin) was
approximately 5-fold higher compared with cells cultured under
normoxia. During the same time, CCR2b mRNA expression was
relatively constant (Figure 5). 
DISCUSSION 
The tumour microenvironment of human epithelial ovarian cancer
comprises a mixture of normal and tumour cells (Burke et al, 1996;
Negus et al, 1997). There is considerable variability within and
between individual biopsies. However, a median of 37% of
the area of each tissue section is occupied by stromal cells, 43%
by epithelial tumour areas, the rest being regions of necrosis
and space (real or artefactual) (Negus et al, 1997). Within
the stromal areas, the majority of infiltrating leukocytes are
CD3+/CD8+/CD45RO+ T cells and CD68+ macrophages. These
cells are also found amongst the epithelial tumour cells. 
The cytokine context of the ovarian tumour microenvironment
is generally proinflammatory. There is frequent expression of
TNF-α , IL-1α , IL-6 and several growth factors, but little expres-
sion of IFN-γ , IL-2, IL-4 and IL-7 that are required for lymphocyte
functions (Burke et al, 1996). CC chemokines are also present and
they may control the leukocyte infiltrate (Negus et al, 1997). The
CC chemokine CCL2 is expressed by both tumour cells and infil-
trating cells (Negus et al, 1995). Correlation between the number
of CCL2 expressing cells and the CD8+ and CD68+ infiltrate
suggested that CCL2 was a predominant chemokine but it was not
clear how the chemokine network was functioning. 
In contrast to our findings with CC chemokines, receptor expres-
sion is limited in solid tumours, with CCR1 predominating. CCR1
mRNA expression correlated with the CD8+ infiltrate, and CCR1
mRNA also appeared to be expressed by macrophages. CCL2 is not
a ligand for this receptor and the major receptor for CCL2, CCR2b,
was not detected in the solid tumours, as has previously been
reported (Sica et al, 2000). CCR2 may be down-regulated by proin-
flammatory cytokines present in solid tumours (Sica et al, 1997). We
did not find any expression of CC chemokine receptors on ovarian
tumour cells, or ovarian cancer cell lines. 
The present study demonstrates the importance of studying both
chemokines and their receptors in a tissue and leads us to suggest
that the CC chemokine network in solid tumours of ovarian cancer
is controlled at the level of CC chemokine receptor. We suggest
that CC chemokines such as CCL2 attract peripheral leukocytes
into the tumour tissue but once there, they lose the ability to
respond to this and other CC chemokines because of receptor
down-regulation. This traps cells in the tumour microenvironment
and changes their chemokine response profile. 
Control of the chemokine network by receptor expression
makes sense. As a range of chemokines are expressed by the
tumours there will be conflicting chemoattractant gradients that an
individual cell can follow. These gradients may be difficult to
regulate with chemokines being retained by the extracellular
matrix. Chemokine receptor expression, in contrast, can be rapidly
modulated by LPS, chemokines, cytokines (Sica et al, 1997;
Chemokine receptor expression in ovarian cancer 895
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Colantonio et al, 1999; Zella et al, 1999) and, as shown in this
paper, hypoxia. Thus, microenvironmental control of chemokine
receptor expression will track an individual cell along an appro-
priate gradient. 
Hypoxia is an important factor in solid tumours; it can be an
important prognostic indicator in gynaecological cancer (Hockel
et al, 1998) and has been shown to regulate the expression of the
chemokines CCL2 (Negus et al, 1998) and CXCL8 (IL-8) (Xu 
et al, 1999) and the chemokine receptor CXCR1 (Grutkoski et al,
1999). Moreover, it is being exploited as a therapeutic strategy in
tumours (Griffiths et al, 2000). Hypoxia was a strong stimulus for
the upregulation of CCR1. The promoter region of this chemokine
receptor has been cloned by Lee et al (direct submission to
Genbank, accession no. AF051305). Analysis of the promoter
sequence using MatInspector V2.2 (Quandt et al, 1995) revealed 2
potential binding sites (at –892 and –760 from the transcriptional
start site) for the transcription factor HIF-1. This transcription
factor is stabilised under hypoxia, and controls the expression of a
number of target genes including VEGF and erythropoietin
(Forsythe et al, 1996; Maxwell and Ratcliffe, 1998) through a
hypoxia responsive element (HRE). HREs always contain the
sequence RCGTG (where R is a purine) which is critical for HIF-1
binding; the flanking residues are also important, but no strong
consensus has been observed. The presence of potential HIF-1-
binding sites suggests that CCR1 could be a target for transcrip-
tional regulation by HIF-1, and could account for the upregulation
seen in THP-1 cells under hypoxic conditions. However, further
work is required to determine if any of these binding sites are func-
tional. Preliminary analysis of the CCR2 promoter sequences
showed no similar HRE consensus sequence in the promoter
region. 
Hypoxia may have time-dependent effects on cell migration
because we have found that hypoxia is a rapid and potent ‘stop’
signal, inhibiting migration after as little as 30 minutes of exposure
(Grimshaw and Balkwill, 2001; Negus et al, 1998; Turner et al,
1999), and this may account for the accumulation of macrophages
seen in areas of necrosis in solid ovarian tumours. The up-
regulation of chemokine receptor expression reported here peaked
much later at 24 hours. 
Tumour-associated macrophages may contribute to tumour
growth and spread providing growth and survival cytokines,
angiogenic factors and proteases for remodelling the extracellular
matrix (Mantovani, 1994; Mantovani et al, 1992). Inhibiting the
tumour infiltrate may inhibit growth and spread of the malignant
cells. Chemokine receptors are an obvious target for such interven-
tion. A recent study of acute and chronic graft rejection models is
of interest. Graft survival in mice with a targeted gene disruption
of CCR1 was significantly prolonged and permanent engraftment
occurred in some of these mice (Gao et al, 2000). We propose that
the CCR1 receptor may also be a therapeutic target in human
epithelial ovarian cancer. 
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